Securities Fraud

Investor Firms Urge Cytokinetics Shareholders to Seek Lead Role in FDA-Disclosure Suit Before Nov. 17

The suit targets alleged misstatements on aficamten’s FDA timing, including the NDA’s filing without a REMS.